Vivet Therapeutics
PrivateLast Round
Grant
Feb 1, 2024
Est. Valuation
$340M
Total Funding Raised
$97.36M
Company Overview
Vivet Therapeutics operates in Healthcare & Life Sciences and is based in Paris. Its latest recorded funding round was a Grant round in February 2024.
Vivet Therapeutics is a biotechnology company that develops novel gene therapy treatments for rare, inherited metabolic diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Vivet Therapeutics Comparables
Compare Vivet Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Ultragenyx Pharmaceutical Inc. | 83% | |
| Genespire | 78% | |
| GEMMA Biotherapeutics | 75% |
For institutional investors. Book with your work email.
Vivet Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Feb 1, 2024 | ||||
| Strategic | Mar 20, 2019 | ||||
| Series A | May 4, 2017 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Vivet Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Roche Venture Fund | Series A |
| Idinvest Partners | Series A |
| Ysios Capital | Series A |
| CVJ | Strategic |
| HealthCap | Series A |
| Roche Venture Fund | Series A |
| Pfizer | Strategic |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 18, 2026
Monthly visitors increased 32% MoM to 5.9K.
- Apr 22, 2026
Monthly visitors increased 61% MoM.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingOct 30, 2026
On Oct 30th '26, Vivet Therapeutics and Mirum Pharmaceuticals are developing pipeline therapies for Progressive Familial Intrahepatic Cholestasis, including VTX-803, which is in preclinical studies for PFIC3.
For institutional investors. Book with your work email.
Vivet Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Vivet Therapeutics's valuation, stock price, and market status.
Is Vivet Therapeutics a public or private company?
Vivet Therapeutics is a private company.
What is the current stock price of Vivet Therapeutics?
Vivet Therapeutics is a private company, so its shares have no public market price. Caplight tracks Vivet Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Vivet Therapeutics worth (valuation)?
Vivet Therapeutics's valuation is estimated at $340.0M based on funding round data.
Can I buy Vivet Therapeutics stock?
Vivet Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Vivet Therapeutics's last funding round?
Vivet Therapeutics's most recent funding round was Grant on February 1, 2024.
Who are the main investors in Vivet Therapeutics?
Key investors in Vivet Therapeutics include Pfizer, Columbus Venture Partners.
Will Vivet Therapeutics IPO soon?
No public IPO plans have been announced for Vivet Therapeutics.
How can I track Vivet Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Vivet Therapeutics's shares on secondary markets.